Oxford BioDynamics PLC - Oxford, England-based biotechnology company has two blood testing products on market, the PSE prostate cancer screening test and the CiRT checkpoint inhibitor response test - Plans to raise £6 million via placing at a minimum price of 0.5 pence per share, a subscription and £500,000 cornerstone investment by OAK Securities. Further, seeks to raise £500,000 via retail offer. The placing will be conducted through an accelerated bookbuilding process. Proceeds will be used as working capital to support the continued commercial development of the EpiSwitch product line through partnerships and collaborations with diagnostic and pharmaceutical companies and direct sales as appropriate.

Current stock price: 0.60 pence, down 33% in London on Tuesday

12-month change: down 98%

Copyright 2025 Alliance News Ltd. All Rights Reserved.